XFOR X4 Pharmaceuticals, Inc. - Common Stock
NASDAQ · Biotechnology · 在 SEC EDGAR 上查看 ↗ 收盘 十月 2, 2026 10-K/10-Q 八月 6, 2026
$2.83
· % 处于52周区间
· 高于低点
· 至高点
$2.7552周低点
$4.8352周高点
市值 (MRQ)
$272M
P/E (TTM)
2.2
EPS (TTM)
$1.27
收入 (TTM)
$9M
您的徽章
52周区间
$3–$5
分析师评级
STRONG BUY
目标价
$12
P/E
2.2
ROE
-113.1%
净利润率
-1029.4%
您的徽章条为空 — 在此页面上任意位置固定一个指标。
XFOR 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
价格
$2.83
市值 (MRQ)
$272M
P/E (TTM)
2.2
EPS (TTM)
$1.27
收入 (TTM)
$9M
ROE (TTM)
-113.1%
52周区间
$3–$5
XFOR 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
区间
条形图
柱状图粒度会根据所选周期进行调整 — 将鼠标悬停在图表上可查看柱状图的开盘价/最高价/最低价/收盘价。
股票拆分
| 除息日 | 拆股 | 类型 |
|---|---|---|
| 2025年4月28日 | 1-for-30 | 反向 |
| 2019年3月14日 | 1-for-6 | 反向 |
10年表现 收入、净利润、利润率和每股收益趋势
收入$6M2018-12-31 → 2025-12-31
EPS$-1.872020-12-31 → 2025-12-31
自由现金流$-86M2018-12-31 → 2025-12-31
净利率-1029.4%2018-12-31 → 2025-12-31
估值与比率
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜？
| 指标 | 5年趋势 | XFOR | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| P/E (TTM) | 2.25年均值 ≈-8.9 | ≈-8.9 | · | · | |
| P/S (TTM) | 31.1 | · | 25.4 | 估值过高 | |
| 市净率 (MRQ) | 1.75年均值 ≈66.7 | ≈66.7 | 2.9 | 公允价值 | |
| Price / FCF (股价/自由现金流) | -3.05年均值 ≈-30.1 | ≈-30.1 | · | · | |
| Price / Cash Flow (市现率) | -3.05年均值 ≈-30.2 | ≈-30.2 | · | · | |
| 市净率（有形资产） (MRQ) | 1.95年均值 ≈58.0 | ≈58.0 | · | · |
同行中位数按每项指标的标准化基础计算，可能与本股票显示的TTM/MRQ基础不完全匹配。
盈利能力 毛利率、营业利润率和净利率；股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
| 指标 | 5年趋势 | XFOR | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 营业利润率 (TTM) | -1003.9% | · | -397.9% | 弱 | |
| 息税折旧摊销前利润率 (TTM) | -984.9% | · | -397.9% | 弱 | |
| 税前利润率 (TTM) | -1029.8% | · | -482.4% | 弱 | |
| 净利润率 (TTM) | -1029.4% | · | -355.9% | 弱 | |
| ROA (TTM) | -50.3%5年均值 ≈-54.3% | ≈-54.3% | -45.0% | 顶尖 | |
| ROE (TTM) | -113.1%5年均值 ≈-123.4% | ≈-123.4% | -68.7% | 弱 | |
| ROIC | -46.7%5年均值 ≈-96.4% | ≈-96.4% | -45.0% | 弱 |
财务健康 债务、流动性、偿付能力 — 资产负债表强度
| 指标 | 5年趋势 | XFOR | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| 流动比率 (MRQ) | 11.35年均值 ≈6.2 | ≈6.2 | 7.8 | 流动性强 | |
| Quick Ratio (速动比率) | 8.45年均值 ≈5.2 | ≈5.2 | 3.9 | 流动性强 |
成长 营收、每股收益 (EPS) 和净利润增长：同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
| 指标 | 5年趋势 | XFOR | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Revenue YoY (营收同比增长) | 150.0% | · | · | · | |
| Revenue CAGR 5Y (营收5年复合年增长率) | 16.7% | · | · | · |
资本效率 资产周转率、库存周转率、应收账款周转率
| 指标 | 5年趋势 | XFOR | 5年均值 | 同行中位数 | 结论 |
|---|---|---|---|---|---|
| Asset Turnover (资产周转率) | 0.05年均值 ≈0.0 | ≈0.0 | 0.2 | 弱 | |
| Receivables Turnover (应收账款周转率) | 7.9 | · | 6.5 | 顶尖 | |
| Revenue / Employee (年营业收入 ÷ 员工人数（报告的 headcount，yfinance）。衍生数据 — 非存储的 SEC-XBRL 概念。) | ≈$144.4K | · | · | · |
价值 · ≈ 5年均值 · 行业中值 · 相对于中值的评判
收益历史 每股收益实际值 vs 预估值，惊喜%，达标率，下次财报日期
平均惊喜
32.2%
下次报告
十一月 03, 2026
| 期间 | 报告 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|---|
| 2026年6月30日 | 八月 6, 2026 | $-0.13 | $-0.18 | 29.2% |
| 2026年3月31日 | $-0.16 | $-0.20 | 21.6% | |
| 2025年12月31日 | $-0.22 | $-0.35 | 37.9% | |
| 2025年9月30日 | $-0.69 | $-0.93 | 26.1% | |
| 2025年6月30日 | $-3.47 | $-4.42 | 21.6% | |
| 2025年3月31日 | $0.04 | $-4.53 | 100.9% | |
| 2024年12月31日 | $-6.00 | $-5.36 | -12.0% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | $6M | $3M | $0 | $0 | $0 | $3M | $0 | $0 | |
| Cost of Revenue | $6M | $797.0K | $0 | $0 | · | · | · | · | |
| R&D Expense | $73M | $82M | $72M | $61M | $51M | $42M | $30M | $20M | |
| SG&A Expense | $44M | $62M | $36M | $27M | $25M | $21M | $18M | $9M | |
| Operating Expenses | · | $39M | $108M | $88M | $85M | $63M | $52M | $29M | |
| Operating Income | $-87M | $-36M | $-108M | $-88M | $-85M | $-60M | $-52M | $-29M | |
| Interest Expense | · | · | $6M | $4M | $4M | $3M | $2M | $720.0K | |
| Interest Income | $5M | $6M | $5M | $219.0K | $10.0K | $273.0K | $1M | $236.0K | |
| Other Non-op | $-753.0K | $332.0K | $554.0K | $-4M | $426.0K | $905.0K | $517.0K | $0 | |
| Pretax Income | $-79M | $-37M | $-101M | $-94M | $-89M | $-62M | $-53M | $-33M | |
| Income Tax | $41.0K | $310.0K | $78.0K | $28.0K | $17.0K | $148.0K | $0 | $0 | |
| Net Income | $-79M | $-37M | $-101M | $-94M | $-89M | $-62M | $-53M | $-33M | |
| EPS (Basic) | $-1.87 | $-5.59 | $-17.07 | $-1.52 | $-3.99 | $-3.09 | · | · | |
| EPS (Diluted) | $-1.87 | $-5.59 | $-17.07 | $-1.52 | $-3.99 | $-3.09 | · | · | |
| Shares (Basic) | 42,292,818 | 6,702,073 | 5,927,082 | 63,525,845 | 25,748,797 | 20,077,000 | · | · | |
| Shares (Diluted) | 42,292,818 | 6,702,073 | 5,927,082 | 63,525,845 | 25,748,797 | 20,077,000 | · | · | |
| EBITDA | $-86M | $-36M | $-107M | $-87M | $-85M | $-60M | $-52M | $-46M |
资产负债表
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $217M | $56M | $99M | $122M | $82M | $79M | $126M | $8M | |
| Receivables | $573.0K | $1M | $0 | · | · | · | $0 | · | |
| Inventory | · | $3M | $0 | · | · | · | · | · | |
| Prepaid Expense | $4M | $6M | $7M | $6M | $5M | $4M | $1M | $1M | |
| Current Assets | $262M | $112M | $122M | $129M | $88M | $83M | $129M | $9M | |
| PP&E (Net) | $182.0K | $776.0K | $745.0K | $1M | $2M | $1M | $403.0K | $241.0K | |
| PP&E (Gross) | $1M | $3M | $2M | $2M | $2M | $2M | $667.0K | $417.0K | |
| Accum. Depreciation | $1M | $2M | $2M | $1M | $724.0K | $274.0K | $264.0K | $176.0K | |
| Goodwill | $17M | $17M | $17M | $17M | $17M | $27M | $27M | $0 | |
| Intangibles | $9M | $10M | $0 | · | · | · | · | · | |
| Other Non-current Assets | $692.0K | $2M | $1M | $1M | $2M | $3M | $2M | $364.0K | |
| Total Assets | $290M | $146M | $147M | $156M | $117M | $123M | $161M | $10M | |
| Accounts Payable | $6M | $9M | $9M | $8M | $4M | $3M | $2M | $3M | |
| Accrued Liabilities | $19M | $23M | $13M | $12M | $8M | $8M | $6M | $3M | |
| Current Liabilities | $26M | $33M | $23M | $22M | $14M | $12M | $9M | $8M | |
| Capital Leases | $0 | $1M | $3M | $4M | $5M | $4M | $2M | · | |
| Other Non-current Liabilities | $525.0K | $831.0K | $432.0K | $173.0K | $826.0K | $462.0K | $16.0K | $205.0K | |
| Total Liabilities | $104M | $124M | $96M | $82M | $53M | $50M | $31M | $22M | |
| Long-term Debt | $75M | $75M | $55M | $32M | $32M | $32M | $20M | $10M | |
| Total Debt | · | · | $55M | $34M | $34M | · | $20M | · | |
| Common Stock | $91.0K | $6.0K | $167.0K | $122.0K | $28.0K | $16.0K | $16.0K | $0 | |
| Retained Earnings | $-595M | $-515M | $-478M | $-377M | $-283M | $-194M | $-132M | $-79M | |
| AOCI | $-109.0K | $-122.0K | $-119.0K | $-119.0K | $-119.0K | $-119.0K | $-119.0K | $0 | |
| Stockholders' Equity | $186M | $22M | $51M | $74M | $64M | $73M | $129M | $-77M | |
| Liabilities + Equity | $290M | $146M | $147M | $156M | $117M | $123M | $161M | $10M | |
| Shares Outstanding | 90,906,920 | 5,698,231 | 167,434,595 | 121,667,250 | 28,127,657 | 16,305,731 | 16,128,862 | 351,652 |
现金流
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| D&A | $1M | $796.0K | $419.0K | $513.0K | $499.0K | $351.0K | $103.0K | $103.0K | |
| Stock-based Comp | $4M | $8M | $9M | $5M | $6M | $5M | $2M | $759.0K | |
| Amort. of Intangibles | · | $500.0K | $0 | $0 | · | · | · | · | |
| Restructuring | $7M | $861.0K | · | · | · | · | · | $2M | |
| Other Non-cash | $-12M | $-102M | $-4M | $11M | $11M | $-2M | $3M | $-4M | |
| Operating Cash Flow | $-86M | $-131M | $-97M | $-77M | $-71M | $-59M | $-48M | $-25M | |
| CapEx | $0 | $326.0K | $60.0K | $103.0K | $615.0K | $1M | $174.0K | $0 | |
| Investing Cash Flow | $8M | $67M | $-15M | $-103.0K | $-615.0K | $-1M | $27M | $0 | |
| Net Debt Issued | $0 | $0 | $-2M | $-795.0K | $0 | $0 | $-9M | $-5M | |
| Stock Issued | $239M | $0 | $60M | · | · | · | · | · | |
| Stock Repurchased | · | · | $0 | $0 | $2M | $0 | $0 | · | |
| Net Stock Activity | $239M | · | $0 | $0 | $-2M | · | · | · | |
| Financing Cash Flow | $239M | $20M | $89M | $117M | $74M | $12M | $141M | $7M | |
| Net Change in Cash | $161M | $-44M | $-23M | $40M | $2M | $-47M | $120M | $-19M | |
| Taxes Paid | $338.0K | · | · | · | · | · | · | · | |
| Free Cash Flow | $-86M | $-131M | $-97M | $-77M | $-72M | $-60M | $-48M | $-41M | |
| Levered FCF | · | · | $-102M | $-81M | $-75M | $-63M | · | · |
盈利能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -1336.7% | -1423.6% | · | · | · | -1995.8% | · | -1311.0% | |
| Net Margin | -1218.5% | -1464.6% | · | · | · | -2071.0% | · | -1229.2% | |
| Pretax Margin | -1217.8% | -1452.5% | · | · | · | -2066.1% | · | -1229.2% | |
| EBITDA Margin | -1317.0% | -1392.5% | · | · | · | -1984.1% | · | -1306.6% | |
| ROA | -36.2% | -25.5% | -66.8% | -68.8% | -73.9% | -43.8% | -61.9% | -73.4% | |
| ROE | -83.2% | -91.6% | -170.5% | -138.1% | -133.3% | -76.5% | -50.7% | 193.4% | |
| ROIC | -46.7% | -165.7% | -101.8% | -81.4% | -86.6% | -82.4% | · | · |
流动性与偿付能力
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 10.2 | 3.4 | 5.3 | 5.8 | 6.3 | 7.0 | 13.7 | 6.5 | |
| Quick Ratio | 8.4 | 1.7 | 4.3 | 5.5 | 5.8 | 6.6 | 13.4 | 5.7 | |
| Debt / Equity | · | · | 1.1 | 0.5 | 0.5 | · | 0.2 | · | |
| LT Debt / Equity | · | · | 1.1 | 0.4 | 0.5 | · | 0.2 | · | |
| Interest Coverage | · | · | -18.6 | -21.9 | -23.4 | -22.3 | -24.1 | -44.2 |
效率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.1 | |
| Inventory Turnover | · | 0.6 | · | · | · | · | · | · | |
| Receivables Turnover | 7.9 | 4.8 | · | · | · | · | · | · |
每股
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $2.05 | $0.13 | $0.31 | $0.61 | $2.29 | $4.46 | $8.01 | $1.48 | |
| Revenue / Share | $0.15 | $0.01 | · | $0.00 | · | · | · | · | |
| Cash Flow / Share | $-2.02 | $-0.65 | $-0.54 | $-1.21 | · | · | · | · | |
| Cash / Share | $2.39 | $0.33 | $0.59 | $1.00 | $2.91 | $4.83 | $7.82 | $2.11 | |
| EPS (TTM) | $-1.87 | $-5.59 | $-17.07 | $-1.52 | $-3.99 | $-3.09 | · | · |
增长率
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 150.0% | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | 16.7% | · | · | · | · | · | · | · |
估值 (TTM)
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $6M | $3M | $0 | $0 | $0 | $3M | $0 | $0 | |
| Net Income TTM | $-79M | $-37M | $-101M | $-94M | $-89M | $-62M | $-53M | $-33M | |
| Market Cap | $364M | $3.76B | $4.21B | $3.62B | $1.93B | $3.15B | $5.18B | $6.09B | |
| Enterprise Value | · | · | $4.17B | $3.54B | $1.88B | · | $5.07B | · | |
| P/E | -2.1 | -3.9 | -1.5 | -19.6 | -17.2 | -62.4 | · | · | |
| P/S | 55.9 | 1447.8 | · | · | · | 1048.5 | · | · | |
| P/B | 2.0 | 170.0 | 82.5 | 48.9 | 30.0 | 43.2 | 40.1 | 281.7 | |
| P / Tangible Book | 2.3 | · | 124.9 | 63.9 | 41.1 | 68.8 | · | · | |
| P / Cash Flow | -4.2 | -28.8 | -43.7 | -47.0 | -27.3 | -53.5 | -107.7 | -148.8 | |
| P / FCF | -4.2 | -28.7 | -43.6 | -46.9 | -27.0 | -52.3 | -107.3 | -148.7 | |
| EV / EBITDA | · | · | -38.9 | -40.6 | -22.3 | · | -98.3 | · | |
| EV / FCF | · | · | -43.2 | -45.8 | -26.3 | · | -105.1 | · | |
| Earnings Yield | -46.8% | -25.4% | -67.8% | -5.1% | -5.8% | -1.6% | · | · |
损益表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2M | $2M | $2M | $2M | $2M | $900.0K | $2M | $560.0K | $563.0K | · | $0 | $0 | $0 | · | · | · | |
| Cost of Revenue | $2M | $598.0K | $364.0K | $351.0K | $326.0K | $5M | $302.0K | $227.0K | $268.0K | $0 | $0 | $0 | $0 | · | · | · | |
| R&D Expense | $15M | $15M | $19M | $17M | $18M | $19M | $22M | $19M | $21M | $20M | $15M | $19M | $16M | $22M | $19M | $14M | |
| SG&A Expense | $9M | $7M | $7M | $12M | $10M | $15M | $15M | $16M | $13M | $17M | $10M | $8M | $10M | $7M | $7M | $6M | |
| Operating Expenses | · | · | · | · | · | · | · | · | · | $37M | · | $27M | $26M | $29M | $26M | $20M | |
| Operating Income | $-16M | $-20M | $-24M | $-28M | $-26M | $-9M | $-36M | $-34M | $71M | $-37M | $-25M | $-27M | $-26M | $-29M | $-26M | $-20M | |
| Interest Expense | · | · | · | · | · | · | · | $2M | $2M | $2M | · | $2M | $1M | $1M | · | $1M | |
| Interest Income | $2M | $2M | $2M | $901.0K | $665.0K | $1M | $1M | $2M | $2M | $1M | $1M | $1M | $914.0K | $835.0K | $198.0K | $14.0K | |
| Other Non-op | $-107.0K | $14.0K | $-7.0K | $-304.0K | $-547.0K | $105.0K | $700.0K | $226.0K | $144.0K | $105.0K | $212.0K | $17.0K | $202.0K | $123.0K | $-4M | $-441.0K | |
| Pretax Income | $-16M | $-20M | $-24M | $-30M | $-26M | $316.0K | $-40M | $-37M | $91M | $-52M | $-19M | $-2M | $-56M | $-24M | $-29M | $-22M | |
| Income Tax | $2.0K | $0 | $0 | $-30.0K | $37.0K | $34.0K | $258.0K | $15.0K | $18.0K | $19.0K | $33.0K | $26.0K | $15.0K | $4.0K | $14.0K | $-13.0K | |
| Net Income | $-16M | $-20M | $-24M | $-30M | $-26M | $282.0K | $-40M | $-37M | $91M | $-52M | $-19M | $-2M | $-56M | $-24M | $-29M | $-22M | |
| EPS (Basic) | $-0.13 | $-0.16 | $2.25 | $-0.69 | $-3.47 | $0.04 | $-5.93 | $-5.48 | $13.59 | $-7.77 | $-16.57 | $-0.01 | $-0.33 | $-0.16 | $0.06 | $-0.26 | |
| EPS (Diluted) | $-0.13 | $-0.16 | $2.25 | $-0.69 | $-3.47 | $0.04 | $-5.91 | $-5.48 | $13.57 | $-7.77 | $-16.57 | $-0.01 | $-0.33 | $-0.16 | $0.06 | $-0.26 | |
| Shares (Basic) | 126,344,020 | 126,288,723 | · | 43,272,773 | 7,412,990 | 6,840,035 | · | 6,695,509 | 6,681,349 | 6,666,386 | · | 196,987,827 | 168,737,764 | 145,967,476 | · | 83,211,000 | |
| Shares (Diluted) | 126,344,020 | 126,288,723 | · | 43,272,773 | 7,412,990 | 6,869,084 | · | 6,695,509 | 6,693,376 | 6,666,386 | · | 196,987,827 | 168,737,764 | 145,967,476 | · | 83,211,000 | |
| EBITDA | $-16M | $-20M | · | $-28M | $-26M | $-9M | · | $-34M | $71M | $-37M | · | $-27M | $-26M | $-29M | · | $-20M |
资产负债表
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | $195M | $217M | $217M | $70M | $39M | $40M | $56M | $97M | $147M | $60M | · | $132M | $136M | $93M | $122M | $80M | |
| Receivables | $2M | $1M | $573.0K | $891.0K | $1M | $509.0K | $1M | $0 | $0 | · | $0 | · | · | · | · | · | |
| Prepaid Expense | $3M | $3M | $4M | $5M | $5M | $4M | $6M | $4M | $5M | $6M | · | $6M | $6M | $4M | · | $5M | |
| Current Assets | $219M | $242M | $262M | $133M | $73M | $96M | $112M | $143M | $175M | $87M | · | $148M | $148M | $98M | · | $86M | |
| PP&E (Net) | $111.0K | $146.0K | $182.0K | $218.0K | $254.0K | $487.0K | $776.0K | $820.0K | $808.0K | $742.0K | · | $772.0K | $868.0K | $986.0K | · | $1M | |
| PP&E (Gross) | $1M | $1M | $1M | · | $1M | $3M | $3M | $3M | $3M | $2M | · | $2M | $2M | $2M | · | $2M | |
| Accum. Depreciation | $1M | $1M | $1M | · | $1M | $2M | $2M | $2M | $2M | $2M | · | $2M | $1M | $1M | · | $1M | |
| Goodwill | $17M | $17M | $17M | $17M | $17M | $17M | $17M | $17M | $17M | $17M | $17M | $17M | $17M | $17M | $17M | $17M | |
| Intangibles | $13M | $9M | $9M | $9M | $10M | $10M | $10M | $10M | $10M | · | · | · | · | · | · | · | |
| Other Non-current Assets | $3M | $704.0K | $692.0K | $2M | $2M | $3M | $2M | $2M | $2M | $1M | · | $1M | $1M | $1M | · | $2M | |
| Total Assets | $253M | $270M | $290M | $164M | $105M | $130M | $146M | $178M | $211M | $112M | · | $173M | $173M | $124M | · | $113M | |
| Accounts Payable | $4M | $5M | $6M | $5M | $8M | $11M | $9M | $9M | $8M | $9M | · | $8M | $5M | $6M | · | $4M | |
| Accrued Liabilities | $14M | $17M | $19M | $17M | $13M | $13M | $23M | $19M | $20M | $13M | · | $16M | $15M | $12M | · | $9M | |
| Current Liabilities | $19M | $24M | $26M | $24M | $23M | $26M | $33M | $29M | $29M | $24M | · | $25M | $22M | $19M | · | $29M | |
| Capital Leases | · | · | $0 | $95.0K | $815.0K | $1M | $1M | $2M | $2M | $2M | · | $3M | $3M | $3M | · | $4M | |
| Other Non-current Liabilities | $523.0K | $526.0K | $525.0K | $525.0K | $535.0K | $567.0K | $831.0K | $1M | $979.0K | $1M | · | $1M | $1M | $350.0K | · | $312.0K | |
| Total Liabilities | $98M | $102M | $104M | $102M | $101M | $107M | $124M | $119M | $116M | $111M | · | $106M | $106M | $73M | · | $52M | |
| Long-term Debt | $75M | $75M | $75M | $75M | $75M | $75M | $75M | $75M | $75M | $55M | · | $55M | $32M | $32M | · | $32M | |
| Total Debt | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | · | $15M | |
| Common Stock | $96.0K | $94.0K | $91.0K | $25.0K | $8.0K | $6.0K | $6.0K | $168.0K | $168.0K | $168.0K | · | $165.0K | $164.0K | $122.0K | · | $69.0K | |
| Retained Earnings | $-631M | $-615M | $-595M | $-571M | $-541M | $-515M | $-515M | $-476M | $-439M | $-530M | · | $-459M | $-456M | $-401M | · | $-348M | |
| AOCI | $-123.0K | $-122.0K | $-109.0K | $-118.0K | $-138.0K | $-128.0K | $-122.0K | $-114.0K | $-159.0K | $-155.0K | · | $-119.0K | $-119.0K | $-119.0K | · | $-119.0K | |
| Stockholders' Equity | $155M | $168M | $186M | $62M | $4M | $23M | $22M | $60M | $94M | $1M | $51M | $68M | $68M | $52M | $74M | $62M | |
| Liabilities + Equity | $253M | $270M | $290M | $164M | $105M | $130M | $146M | $178M | $211M | $112M | · | $173M | $173M | $124M | · | $113M | |
| Shares Outstanding | 96,114,534 | 94,319,696 | 90,906,920 | 25,146,411 | 7,959,947 | 5,788,745 | 5,698,231 | 168,511,264 | 168,196,180 | 167,937,781 | · | 164,705,712 | 164,418,011 | 122,207,488 | · | 68,734,553 |
现金流
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $997.0K | $223.0K | $223.0K | $223.0K | $355.0K | $476.0K | $273.0K | $267.0K | $194.0K | $62.0K | $62.0K | $104.0K | $126.0K | $127.0K | $124.0K | $124.0K | |
| Stock-based Comp | $3M | $2M | $2M | $760.0K | $748.0K | $519.0K | $2M | $2M | $2M | $2M | $3M | $2M | $2M | $2M | $1M | $1M | |
| Amort. of Intangibles | · | · | · | $200.0K | · | · | · | $200.0K | $100.0K | · | · | · | · | · | · | · | |
| Restructuring | $198.0K | $37.0K | $-196.0K | · | · | · | · | · | · | · | · | · | · | · | · | · | |
| Other Non-cash | · | $-2M | · | · | · | $-14M | · | · | · | $16M | · | · | · | $-4M | · | · | |
| Operating Cash Flow | $-21M | $-20M | $-16M | $-28M | $-30M | $-12M | $-33M | $-34M | $-64M | $-34M | $47M | $-69M | $-48M | $-27M | $-19M | $-19M | |
| CapEx | · | · | $0 | $0 | $0 | $0 | $41.0K | $92.0K | $134.0K | $59.0K | $35.0K | $8.0K | $8.0K | $9.0K | $34.0K | $9.0K | |
| Investing Cash Flow | $-1M | $19M | $17M | $-29M | $23M | $-3M | $-9M | $-16M | $97M | $-5M | $-5M | $-5M | $-5M | $-9.0K | $-34.0K | $-9.0K | |
| Stock Issued | · | · | $146M | $87M | · | · | $0 | $-159.0K | · | · | $51M | $2.0K | · | · | · | $0 | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | · | · | $443.0K | · | · | |
| Net Stock Activity | · | · | · | · | · | · | · | · | · | · | · | · | · | $-443.0K | · | · | |
| Financing Cash Flow | $75.0K | $2.0K | $146M | $87M | $6M | $0 | $135.0K | $0 | $20M | $0 | $97.0K | $21M | $69M | $-2M | $61M | $52M | |
| Net Change in Cash | $-22M | $-365.0K | $147M | $30M | $-1M | $-15M | $-42M | $-50M | $87M | $-39M | $-32M | $-5M | $43M | $-29M | $42M | $32M | |
| Free Cash Flow | · | · | · | · | · | $-12M | · | · | · | $-34M | · | · | · | $-27M | · | · | |
| Levered FCF | · | · | · | · | · | · | · | · | · | $-36M | · | · | · | $-28M | · | · |
盈利能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating Margin | -683.0% | -812.2% | · | -1756.6% | -1504.1% | -1049.2% | · | -6160.7% | 12629.3% | · | · | · | · | · | · | · | |
| Net Margin | -673.2% | -809.6% | · | -1903.9% | -1476.0% | 31.3% | · | -6552.9% | 16133.8% | · | · | · | · | · | · | · | |
| Pretax Margin | -673.1% | -809.6% | · | -1905.8% | -1473.8% | 35.1% | · | -6550.2% | 16136.9% | · | · | · | · | · | · | · | |
| EBITDA Margin | -683.0% | -803.3% | · | -1756.6% | -1504.1% | -996.3% | · | -6160.7% | 12629.3% | · | · | · | · | · | · | · | |
| ROA | -9.0% | -10.1% | · | -17.4% | -16.3% | 0.23% | · | -20.9% | 62.3% | -48.9% | · | -1.3% | · | · | · | -18.5% | |
| ROE | -20.3% | -21.1% | · | -49.2% | -52.3% | 2.4% | · | -57.7% | 145.9% | -204.0% | · | -3.4% | · | · | · | -33.1% | |
| ROIC | -10.5% | -12.0% | · | -44.6% | -661.5% | -36.7% | · | -57.9% | 75.3% | -3600.7% | · | -40.7% | · | · | · | -26.3% |
流动性与偿付能力
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 11.3 | 10.2 | · | 5.6 | 3.2 | 3.7 | · | 4.9 | 6.1 | 3.7 | · | 5.8 | · | · | · | 3.0 | |
| Quick Ratio | 10.2 | 9.2 | · | 3.0 | 1.8 | 1.6 | · | 3.3 | 5.1 | 2.6 | · | 5.2 | · | · | · | 2.8 | |
| Debt / Equity | · | · | · | · | · | · | · | · | · | · | · | 0.0 | · | · | · | 0.2 | |
| Interest Coverage | · | · | · | · | · | · | · | -14.3 | 32.7 | -19.9 | · | -16.7 | -22.5 | -26.4 | · | -19.8 |
效率
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.0 | 0.0 | · | 0.0 | 0.0 | 0.0 | · | 0.0 | 0.0 | · | · | · | · | · | · | · | |
| Receivables Turnover | 1.5 | 3.1 | · | 3.5 | 3.0 | 0.5 | · | · | · | · | · | · | · | · | · | · |
每股
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Book Value / Share | $1.62 | $1.79 | · | $2.45 | $0.50 | $3.96 | · | $0.35 | $0.56 | $0.01 | · | $0.41 | · | · | · | $0.90 | |
| Revenue / Share | $0.02 | $0.02 | · | $0.04 | $0.24 | $0.13 | · | $0.00 | $0.00 | · | · | · | · | · | · | · | |
| Cash Flow / Share | · | $-0.16 | · | · | · | $-1.80 | · | · | $-0.32 | $-0.17 | · | $-0.35 | $-0.28 | $-0.18 | · | · | |
| Cash / Share | $2.03 | $2.30 | · | $2.77 | $4.93 | $6.95 | · | $0.58 | $0.88 | $0.36 | · | $0.80 | · | · | · | $1.16 | |
| EPS (TTM) | $1.27 | $-2.07 | · | $-10.03 | $-14.82 | $2.22 | · | $-16.25 | $-10.78 | $-24.68 | · | $-0.44 | $-0.69 | $-0.96 | · | $-2.86 |
估值 (TTM)
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $9M | $8M | · | $6M | $5M | $4M | · | · | · | · | · | · | · | $0 | · | $0 | |
| Net Income TTM | $-90M | $-100M | · | $-95M | $-102M | $15M | · | $-17M | $18M | $-129M | · | $-111M | $-130M | $-96M | · | $-95M | |
| Market Cap | $449M | $390M | · | $86M | $15M | $41M | · | $3.38B | $2.93B | $7.00B | · | $5.39B | · | · | · | $3.53B | |
| Enterprise Value | · | · | · | · | · | · | · | · | · | · | · | $5.25B | · | · | · | $3.46B | |
| P/E | 3.7 | -2.0 | · | -0.3 | -0.1 | 3.2 | · | -1.2 | -1.6 | -1.7 | · | -74.3 | -84.3 | -27.2 | · | -17.9 | |
| P/S | 51.3 | 48.4 | · | 15.2 | 3.2 | 11.6 | · | · | · | · | · | · | · | · | · | · | |
| P/B | 2.9 | 2.3 | · | 1.4 | 3.8 | 1.8 | · | 56.7 | 31.0 | 6759.7 | · | 79.7 | · | · | · | 57.0 | |
| P / Tangible Book | 3.6 | 2.7 | · | 2.5 | · | · | · | 105.4 | 43.9 | · | · | 107.2 | · | · | · | 79.2 | |
| P / Cash Flow | · | -19.9 | · | · | · | -3.3 | · | · | -45.8 | -208.4 | · | -78.3 | · | · | · | · | |
| Earnings Yield | 27.2% | -50.1% | · | -293.3% | -780.0% | 31.4% | · | -81.0% | -62.0% | -59.2% | · | -1.4% | -1.2% | -3.7% | · | -5.6% |
最近期在左侧 · 空值显示为 ·
财务报表 损益表、资产负债表、现金流量表 — 年度，近5年
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 收入 | $6M | $3M | $0 | $0 | $0 |
| 营业利润率 % | -1336.7% | -1423.6% | · | · | · |
| 净收入 | $-79M | $-37M | $-101M | $-94M | $-89M |
| 稀释后每股收益 (EPS) | $-1.87 | $-5.59 | $-17.07 | $-1.52 | $-3.99 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 负债/股东权益比率 | · | · | 1.1 | 0.5 | 0.5 |
| 流动比率 | 10.2 | 3.4 | 5.3 | 5.8 | 6.3 |
| 速动比率 | 8.4 | 1.7 | 4.3 | 5.5 | 5.8 |
| 指标 | 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 |
|---|---|---|---|---|---|
| 自由现金流 | $-86M | $-131M | $-97M | $-77M | $-72M |
机构持有人 (13F) 93 家申报者 · $463.3M 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸；单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存，而非方向性判断。
持有人
93
持有价值
$463.3M
新仓位
36
已退出持仓
26
机构活动 — Q2 2026 与上一季度对比
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 36 (+18 与上一季度对比) | 26 (+17 与上一季度对比) | 23 (+1 与上一季度对比) | 13 (-8 与上一季度对比) | +8.7M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天，外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过，优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| MORGAN STANLEY | $44184173 | 9461279 | 9.54% | 股份 |
| FMR LLC | $38862138 | 8321657 | 8.39% | 股份 |
| Bain Capital Life Sciences Investors, LLC | $37208011 | 7967454 | 8.03% | 股份 |
| PERCEPTIVE ADVISORS LLC | $37049403 | 7933491 | 8.00% | 股份 |
| Saturn V Capital Management LP | $32565512 | 6973343 | 7.03% | 股份 |
| Empery Asset Management, LP | $32365860 | 6930591 | 6.99% | 股份 |
| Deep Track Capital, LP | $27453795 | 5878757 | 5.93% | 股份 |
| BlackRock, Inc. | $25941411 | 5554906 | 5.60% | 股份 |
| Kalehua Capital Management LLC | $17385663 | 3722840 | 3.75% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $17353062 | 3715859 | 3.75% | 股份 |
| Rosalind Advisors, Inc. | $15012957 | 3214766 | 3.24% | 股份 |
| VANGUARD GROUP INC | $13694648 | 3423662 | 2.96% | 股份 |
| BRAIDWELL LP | $13649261 | 2922754 | 2.95% | 股份 |
| Blackstone Inc. | $12524576 | 2681922 | 2.70% | 股份 |
| Trails Edge Capital Partners, LP | $12008803 | 2571478 | 2.59% | 股份 |
| Nantahala Capital Management, LLC | $11439016 | 2449468 | 2.47% | 股份 |
| BVF INC/IL | $10431575 | 2233742 | 2.25% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $9800562 | 2098047 | 2.12% | 股份 |
| Venrock Adviser, LLC | $9032962 | 1934253 | 1.95% | 股份 |
| SAMSARA BIOCAPITAL, LLC | $6517391 | 1395587 | 1.41% | 股份 |
| STATE STREET CORP | $6052399 | 1296017 | 1.31% | 股份 |
| Woodline Partners LP | $4675114 | 1001095 | 1.01% | 股份 |
| GOLDMAN SACHS GROUP INC | $4280223 | 916536 | 0.92% | 股份 |
| NORTHERN TRUST CORP | $3048805 | 652849 | 0.66% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $2671417 | 572038 | 0.58% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $2531738 | 542128 | 0.55% | 股份 |
| Verdad Advisers, LP | $1644274 | 352093 | 0.35% | 股份 |
| CHARLES SCHWAB INVESTMENT MANAGEMENT INC | $1229443 | 263264 | 0.27% | 股份 |
| SUSQUEHANNA INTERNATIONAL GROUP, LLP | $1168901 | 250300 | 0.25% | 买入期权 |
| Caption Management, LLC | $1167500 | 250000 | 0.25% | 买入期权 |
| Stonepine Capital Management, LLC | $1050699 | 224989 | 0.23% | 股份 |
| Bank of New York Mellon Corp | $916908 | 196340 | 0.20% | 股份 |
| Affinity Asset Advisors, LLC | $677150 | 145000 | 0.15% | 股份 |
| Nuveen, LLC | $501507 | 107389 | 0.11% | 股份 |
| Invesco Ltd. | $451926 | 96772 | 0.10% | 股份 |
| ALPS ADVISORS INC | $447040 | 95726 | 0.10% | 股份 |
| RHUMBLINE ADVISERS | $444022 | 95081 | 0.10% | 股份 |
| Susquehanna Portfolio Strategies, LLC | $407607 | 87282 | 0.09% | 股份 |
| DEUTSCHE BANK AG\ | $368393 | 78885 | 0.08% | 股份 |
| AMERICAN CENTURY COMPANIES INC | $349293 | 74795 | 0.08% | 股份 |
| CITIGROUP INC | $327423 | 70112 | 0.07% | 股份 |
| WELLS FARGO & COMPANY/MN | $316215 | 67712 | 0.07% | 股份 |
| Palumbo Wealth Management LLC | $313432 | 67116 | 0.07% | 股份 |
| Squarepoint Ops LLC | $313254 | 67078 | 0.07% | 股份 |
| UBS Group AG | $271060 | 58043 | 0.06% | 股份 |
| WELLINGTON MANAGEMENT GROUP LLP | $241906 | 51800 | 0.05% | 股份 |
| MetLife Investment Management, LLC | $224015 | 47969 | 0.05% | 股份 |
| BANK OF AMERICA CORP /DE/ | $218841 | 46861 | 0.05% | 股份 |
| Point72 Asset Management, L.P. | $191806 | 41072 | 0.04% | 股份 |
| MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. | $173131 | 37073 | 0.04% | 股份 |
激进投资者及 5%+ 股东 10 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权，意图影响发行人（激进股东持股、董事会活动、并购）。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Growth Equity Opportunities 18 VGE, LLC, NEA 18 Venture Growth Equity, L.P., NEA Partners 18 VGE, L.P., NEA 18 VGE GP, LLC, Ali Behbahani, Carmen Chang, Anthony A. Florence, Jr., Mohamad H. Makhzoumi, Edward T. Mathers, Scott D. Sandell, Paul Walker, Rick Yang ×5 申报 | 2025年10月29日 | 6.20% | 修订 | 被动投资 | SEC |
| Coastlands Capital LP, Coastlands Capital Partners LP, Coastlands Capital GP LLC, Coastlands Capital LLC, Matthew D. Perry | 2025年8月18日 | 9.99% | 初始申报 | · | SEC |
| Bain Capital Life Sciences Fund, L.P., Bain Capital Life Sciences Fund II, L.P., BCIP Life Sciences Associates, LP, BCLS II Investco, LP, BCLS I Investco, LP | 2025年8月13日 | 9.99% | 初始申报 | · | SEC |
| Polaris Venture Partners V, L.P. (“PVP V”), Polaris Venture Partners Entrepreneurs’ Fund V, L.P. (“PVPE V”), Polaris Venture Partners Founders’ Fund V, L.P. (“PVPFF V”), Polaris Venture Partners Special Founders’ Fund V, L.P. (“PVPSFF V”), Polaris Venture Management Co. V, L.L.C. (“PVM V”), Jonathan A. Flint, Terrance G. McGuire ×2 申报 | 2019年7月17日 | · | 初始申报 | · | SEC |
| 2019年5月28日 | · | 初始申报 | · | SEC | |
| Paula Ragan, Ph.D. ×2 申报 | 2019年4月26日 | · | 初始申报 | 并购/出售 | SEC |
| OrbiMed Advisors LLC, OrbiMed Capital GP IV LLC ×3 申报 | 2019年3月19日 | · | 初始申报 | · | SEC |
| X4 Pharmaceuticals, Inc. | 2018年12月6日 | · | 初始申报 | 并购/出售 | SEC |
| SVLSF V, LLC, SV Life Sciences Fund V, L.P., SV Life Sciences Fund V Strategic Partners, L.P., SV Life Sciences Fund V (GP), L.P., SVLSF VI, LLC, SV Life Sciences Fund VI, LP., SV Life Sciences Fund VI Strategic Partners, L.P., SV Life Sciences Fund VI (GP), L.P. | 2018年2月14日 | · | 初始申报 | 被动投资 | SEC |
| New Enterprise Associates 16, L.P., NEA Partners 16, L.P., NEA 16 GP, LLC, Peter J. Barris, Forest Baskett, Anthony A. Florence, Jr., Mohamad H. Makhzoumi, Joshua Makower, David M. Mott, Chetan Puttagunta, Jon M. Sakoda, Scott D. Sandell, Peter W. Sonsini, Ravi Viswanathan | 2017年11月29日 | · | 初始申报 | 被动投资 | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
公司内部人士 39 位内幕人士 · 17 位高管 · 21 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Paula Ragan | President and CEO | 2025年2月12日 A | 3337386 | 0 | 0 | $0 |
| Michael Gray | President, CEO and CFO | 2018年11月27日 A | 250000 | 0 | 0 | $0 |
| David Kirske | Chief Financial Officer | 2026年6月30日 S | 167750 | 0 | 2 | $-109156 |
| Adam S. Mostafa | Chief Financial Officer | 2025年2月12日 A | 850000 | 0 | 0 | $0 |
| John Volpone | President | 2026年8月12日 S | 265305 | 0 | 1 | $-109117 |
| Mary Dibiase | Chief Operating Officer | 2025年2月12日 A | 1140980 | 0 | 0 | $0 |
| Adam R Craig | Executive Chairman | 2026年8月12日 S | 328651 | 0 | 1 | $-210616 |
| Natasha Fay Thoren | Chief Legal Officer | 2025年5月20日 A | 9462 | 0 | 0 | $0 |
| Mark Baldry | Chief Commercial Officer | 2025年5月16日 A | 25337 | 0 | 0 | $0 |
| Christophe Arbet-Engels | Chief Medical Officer | 2025年2月12日 A | 864207 | 0 | 0 | $0 |
| Arthur Taveras | Chief Scientific Officer | 2024年10月7日 S | 388026 | 0 | 0 | $0 |
| Derek M Meisner | Chief Legal Officer | 2022年8月17日 S | 145155 | 0 | 0 | $0 |
| Diego Cadavid | Chief Medical Officer | 2022年3月1日 A | 104107 | 0 | 0 | $0 |
| Renato Skerlj | Chief Scientific Officer | 2020年9月9日 S | 42076 | 0 | 0 | $0 |
| Lynne E Kelley | Chief Medical Officer | 2019年4月24日 A | · | 0 | 0 | $0 |
| Eszter Nagy | Chief Scientific Officer | 2018年3月7日 A | · | 0 | 0 | $0 |
| David Mantus | Chief Development Officer | 2018年3月7日 A | · | 0 | 0 | $0 |
| Kelly Gold | 董事 | 2026年7月1日 A | · | 0 | 0 | $0 |
| Francoise De Craecker | 董事 | 2026年1月1日 A | 4722 | 0 | 0 | $0 |
| Murray Stewart | 董事 | 2026年1月1日 A | 7883 | 0 | 0 | $0 |
| Gary Bridger | 董事 | 2026年1月1日 A | 4722 | 0 | 0 | $0 |
| Michael S Wyzga | 董事 | 2026年1月1日 A | 5555 | 0 | 0 | $0 |
| Keith Woods | 董事 | 2025年6月9日 A | 6000 | 0 | 0 | $0 |
| William Aliski | 董事 | 2024年6月10日 A | 96667 | 0 | 0 | $0 |
| Alison Frances Lawton | 董事 | 2024年6月10日 A | 96667 | 0 | 0 | $0 |
| David W J Mcgirr | 董事 | 2024年6月10日 A | 96667 | 0 | 0 | $0 |
| Rene Russo | 董事 | 2021年6月2日 A | · | 0 | 0 | $0 |
| Isaac Blech | 董事 | 2019年3月13日 A | · | 0 | 0 | $0 |
| Tillman U. Gerngross | 董事 | 2018年6月5日 A | 392821 | 0 | 0 | $0 |
| Claudio Nessi | 董事 | 2018年6月5日 A | 867639 | 0 | 0 | $0 |
| Amy Schulman | 董事 | 2018年6月5日 A | · | 0 | 0 | $0 |
| William D Clark | 董事 | 2018年6月5日 A | · | 0 | 0 | $0 |
| GORDON CARL L | 董事 | 2018年6月5日 A | 1868966 | 0 | 0 | $0 |
| Terrance McGuire | 董事 | 2018年6月5日 A | 18031 | 0 | 0 | $0 |
| Michael Jay Ross | 董事 | 2017年11月15日 A | 1868961 | 0 | 0 | $0 |
| Anna-Maria & Stephen Kellen Foundation, Inc. | 10% 所有者 | 2017年11月20日 C | 124381 | 0 | 0 | $0 |
| Bill & Melinda Gates Foundation | 10% 所有者 | 2017年11月20日 C | 722179 | 0 | 0 | $0 |
| Alexandria Venture Investments, LLC | 10% 所有者 | 2017年11月15日 C | 225680 | 0 | 0 | $0 |
| Anthony Chris Stevens | · | 2018年3月7日 A | · | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士；净额=仅公开市场买卖
ETF持仓 由 11 只交易所交易基金持有
权重仅反映直接股权持仓（N-PORT）；杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| QQQS · Invesco Exchange-Traded Fund Trus... | 0.36% | 29512 SH | 2026年10月2日 | 每日 |
| IWC · iShares Trust | 0.06% | 273306 SH | 2026年9月11日 | 每日 |
| VTWV · VANGUARD SCOTTSDALE FUNDS | 0.02% | 70293 SH | 2026年8月19日 | 每日 |
| RSSL · Global X Funds | 0.01% | 38483 NS | 2026年7月31日 | N-PORT |
| VTWO · VANGUARD SCOTTSDALE FUNDS | 0.01% | 464950 SH | 2026年8月19日 | 每日 |
| IWM · iShares Trust | 0.01% | 2014836 SH | 2026年9月11日 | 每日 |
| PRFZ · Invesco Exchange-Traded Fund Trust | 0.01% | 48548 SH | 2026年10月2日 | 每日 |
| VXF · VANGUARD INDEX FUNDS | 0.00% | 1031672 SH | 2026年8月19日 | 每日 |
| VTI · VANGUARD INDEX FUNDS | 0.00% | 2599387 SH | 2026年8月19日 | 每日 |
| VTHR · VANGUARD SCOTTSDALE FUNDS | 0.00% | 6885 SH | 2026年8月19日 | 每日 |
| IWN · iShares Trust | · | 753604 SH | 2026年9月11日 | 每日 |
XFOR 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
评级 · 11 位分析师
买入
中位数目标
$12.00
+324.0%
5 45.5%
强烈买入
5 45.5%
买入
1 9.1%
持有
0 0.0%
卖出
0 0.0%
强烈卖出
12个月价格目标
5 位分析师 · 2026-09-29平均目标 $11.60 +309.9%
← 低于所有目标
当前价格 $2.83
最低$10.00
平均值$11.60
最高$13.00
同行比较（GICS 子行业） 关键指标与行业同行对比
财年依据，价格截至各公司上一个财年末收盘价。
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| XFOR | $364M | -2.1 | 150.0% | -1218.5% | -83.2% | · |
| RZLT | $501M | -6.9 | · | · | -67.8% | · |
| KYTX | $568M | -2.6 | · | · | -77.4% | · |
| IRD | $140M | -2.5 | 29.1% | -349.3% | -302.2% | · |
| AGEN | $111M | · | 10.4% | -2.7% | 1.0% | · |
| ENTA | $256M | -3.1 | -3.4% | -125.4% | -103.5% | · |
| ARCT | $174M | -2.6 | -46.1% | -80.2% | -29.6% | · |
| INDP | $6M | -0.1 | · | · | -2820.8% | · |
| CCCC | $185M | -1.5 | 1.0% | -292.1% | -48.8% | · |
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 + 号。
您的选择已保存，并会跟随您浏览所有股票。
来源：SEC 10-Q 于 八月 6, 2026 申报